Mary Kay Inspires Beauty Trends at Spring/Summer 2020 Fashion Weeks in Europe
20.12.2019 02:06:00 EET | Business Wire | Press release
Mary Kay Inc. continues to make its mark on the beauty industry through its ongoing partnerships with Ukrainian and Belarus Fashion Weeks, Mercedes-Benz Fashion Week Russia, and Bratislava Fashion Days in Slovakia and Czech Republic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191219005838/en/
Mercedes-Benz Fashion Week Russia (Photo: Mary Kay Inc.)
“As an innovator of beauty trends, Mary Kay along with beauty artists, unveiled 2020 runway looks throughout fashion weeks in Europe,” stated Tara Eustace, President of Mary Kay for the European Region. “The runways at fashion week are the perfect stage to share inspiration, debut our innovations with the fashion world and elevate makeup trends in each of these countries.”
Designers, influencers, celebrities, makeup artists, beauty bloggers and editors attended all five events where Mary Kay was the official beauty partner for the spring/summer 2020 fashion week season.
“The Mary Kay Global Design Studio was created over 10 years ago to inspire beauty trends and drive innovation, fueling creativity and individuality through fashion collaborations around the world,” said Sheryl Adkins-Green, Chief Marketing Officer, and Creative & Inspiration Officer for the Mary Kay Global Design Studio. “During fashion weeks, makeup artists in collaboration with Mary Kay, unleashed some of the major trends of the season. Beauty enthusiasts can get the look ‘as seen’ on the runway or revisit the inspiration to create their own.”
Fashion Weeks Highlights:
Held in Kyiv between August 31-September 4, 2019, Ukrainian Fashion Week (UFW) kicked off the Mary Kay sponsored events in Europe. Under the artistic direction of lead makeup artist MartElle, a team of 40 beauty artists, all of whom are also members of the Mary Kay independent sales force, prepped the runway models for 30 Ukrainian designers and performed 350 different makeup looks throughout UFW. One of the fashion shows was an exclusive capsule pink bra collection collaboration between Mary Kay Ukraine and lingerie brand Keòsme aimed at supporting women diagnosed with breast cancer. Ten percent of sales proceeds from the exclusive collection will be donated to a Ukrainian nonprofit organization that promotes female health and wellness.
Bratislava Fashion Days by Mercedes-Benz was next in Bratislava on September 16-19, and Prague on October 5-6. For the second year in a row, Mary Kay Slovakia was the Official Makeup Artist for the event. Makeup artists prepared the show-stopping makeup looks worn by runway models and starred in the backstage stories on Fashion TV. Inspired by Mary Kay’s Global Beauty Ambassador Luis Casco, the “Sparkling Pewter,” “Sultry Glam,” “Sweet Champagne,” and “Garnet Gold” special looks became the highlights of the shows. The December 17 show in Bratislava marked the closing of the 2019 edition of the Fashion Days.
Mary Kay Russia has been the Official Makeup Artist of the Mercedes-Benz Fashion Week Russia (MBFW Russia) for 7 years in a row—13 consecutive seasons. The largest fashion event in Eastern Europe, MBFW Russia was held in Moscow on October 15-19. Luis Casco, and star makeup artist Andrey Shilkov, co-created the looks for 109 shows out of a total of 119, while a makeup team from the Mary Kay Russia independent sales force represented the brand backstage. The stunning beauty look imagined for the Te Amo Couture runway show was the result of the exclusive Casco-Shilkov collaboration.
The Belarus Fashion Week (BFW) held in Minsk on October 17- 20, 2019, wrapped up a successful fashion week season for Mary Kay in Eastern Europe. Mary Kay was BFW Official Makeup Artist for the 7th season in a row. A team of beauty artists from the Mary Kay Belarus independent sales force featured 650 runway looks and no less than 500 makeovers under the guidance of beauty artist maestro Alexander Kiryniuk, who also presented the season's trends.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 55 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191219005838/en/
Contact information
Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom